GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (XAMS:VVY) » Definitions » Total Operating Expense

Vivoryon Therapeutics NV (XAMS:VVY) Total Operating Expense : €20.96 Mil (TTM As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Vivoryon Therapeutics NV Total Operating Expense?

Vivoryon Therapeutics NV's Total Operating Expense for the six months ended in Dec. 2024 was €7.16 Mil. Vivoryon Therapeutics NV's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was €20.96 Mil.

Vivoryon Therapeutics NV Total Operating Expense Historical Data

The historical data trend for Vivoryon Therapeutics NV's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivoryon Therapeutics NV Total Operating Expense Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.01 22.09 29.06 25.74 20.96

Vivoryon Therapeutics NV Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.68 10.69 14.53 13.81 7.16

Vivoryon Therapeutics NV Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €20.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivoryon Therapeutics NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (XAMS:VVY) » Definitions » Total Operating Expense
Comparable Companies
VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 OCSE:GMAB INSM BMRN HKSE:02269 SHSE:603392 INCY HKSE:09926
Traded in Other Exchanges
0R3M:UK 05Y:Germany VVYN:Austria
Address
Weinbergweg 22, Halle, SN, DEU, 06120
Website
https://www.vivoryon.com
Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV Headlines

No Headlines